

FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ANALYSIS REPORT

| | | | |
|--------------------------------|-----------------|------------------------------|-----------|
| Principal Investigator: | JOHN DOE, Ph.D. | Cytogenetics Number: | CL-XXXX |
| Submitted By: | JANE POSTDOC | Customer Specimen ID: | XXXXXX |
| | | Passage Date: | 7/13/2014 |
| | | Received Date: | 7/14/2014 |
| | | Reported Date: | 7/15/2014 |

Results: Abnormal FISH result for CKS1B/CDKN2C (Cytocell)

FISH ANALYSIS :

| Probe | Chromosome Target | Result |
|--------------------------------|---------------------|-------------------|
| CKS1B/CDKN2C (Cytocell) | 1q21, 1p32.3 | *POSITIVE* |

FISH INTERPRETATION :

*** 1) FISH for chromosome 1 was performed on 200 interphase cells using two probes: CDKN2C at 1p32.3 and CKS1B at 1q21. Three signals for both CDKN2C at 1p32.3 and CKS1B at 1q21 were seen in 22 out of 200 (11.0%) interphase cells examined, indicating trisomy of chromosome 1. Four signals for both CDKN2C at 1p32.3 and CKS1B at 1q21 were seen in 17 out of 200 (8.5%) interphase cells examined, suggesting tetrasomy (4 copies) of chromosome 1. There was no evidence of chromosome 1 abnormalities in 147 out of 200 (73.5%) interphase cells examined. The remaining 14 interphase cells showed other abnormalities under our threshold for positivity.**

A control subject processed simultaneously showed a normal signal pattern in all 40 interphase nuclei examined.

ISCN diagnosis: nuc ish (CDKN2C,CKS1B)x2[147/200]/CDKN2C,CKS1B)x3[22/200]/(CDKN2C,CKS1B)x4[17/200]

Note: These FISH tests were developed and their performance characteristics determined by Diagnostic Cytogenetics, Inc.. They have not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes. They should not be regarded as investigational or for research. This laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing.

Reviewed By: _____
INDIRA MEHTA, Ph.D.

JOHN DOE, Ph.D.
125 STREET AVE
ROOM 101
CITY, ST 11111